Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04582487
Other study ID # ALL2720
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 19, 2021
Est. completion date May 2024

Study information

Verified date February 2024
Source Gruppo Italiano Malattie EMatologiche dell'Adulto
Contact Paola Fazi
Phone 0670390528
Email p.fazi@gimema.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic screening to identify novel potential therapeutic approach and thus, eligibility for treatment based on molecular and DSRP data. As soon as genomic and DSRP profiling are made available, local Investigator can submit to local ethic committee a request for clinical use of identified compound.


Description:

This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic screening to identify novel potential therapeutic approach and thus, eligibility for treatment based on molecular and DSRP data. Genomic studies include karyotyping, CI-FISH and sequencing of 72 selected genes recurrently involved in T-ALL (by NGS). A panel of 80 compounds has been choosen for DSRP profile. As soon as genomic and DSRP profiling are made available, local Investigator can submit to local ethic committee a request for clinical use of compound hits. Meanwhile, in case of leukocytosis and uncontrolled disease, patients will be treated with cytoreductive therapies and best supportive care according to guidelines and scientific consensus. Every patient will receive a molecularly and functionally informed therapy following the therapeutic schedule already defined by in other tumors. Treatment will be selected on the basis of integration of genomic and small response data.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients to be enrolled in this study must have T-cell ALL or T-cell lymphoblastic lymphoma (LL) in the first relapse or must have failed primary induction chemotherapy (i.e., never attained a complete remission following an initial course of standard therapy for T-ALL/LBL or have a diagnosis of ETP-ALL [T-ALL with the following phenotype: Negative: CD1a-, CD8-, CD4-, CD5 (less than 75% of blasts); CD13+, CD33+, CD34+, CD117+, HLA-DR+, CD11b+, and/or CD65+ -in at least 25% of lymphoblasts - Ages Eligible for Study: over 18 years - Patients with T-ALL/LBL must have greater than 5% blasts in the bone marrow with or without extramedullary disease - Patients with T-ALL/LBL must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis - Patients may have CNS 1 (WBC count in CSF <5 and having no blasts) or CNS 2 (WBC count in CSF <5 and having blasts) disease but not CNS 3 (WBC count in CSF =5 and having blasts) - ECOG 0-2 or Karnofsky = 50% - Patients may be enrolled on study regardless of the timing of prior Intrathecal therapy; however, they may not begin treatment on this protocol until a minimum of 7 days has elapsed since prior intrathecal therapy - Adequate renal function defined as serum creatinine = 1.5x upper limit of normal (ULN) for age. If the serum creatinine is above these values, the calculated creatinine clearance or radioisotope GFR must be = 70 mL/min/1.73m2 - Total bilirubin = 1.5x ULN for age. If the total bilirubin is elevated, patient will still be eligible if the conjugated (direct) serum bilirubin = ULN for age - ALT = 5x ULN of normal for age - Adequate cardiac function defined as shortening fraction of = 27% by echocardiogram or ejection fraction = 45% by gated radionuclide study - No evidence of dyspnea at rest - No exercise intolerance - A pulse oximetry = 94% at sea level (= 90% at altitude = 5000 feet) if there is clinical indication for determination - Patients must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients must sign a written informed consent Exclusion Criteria: - Significant organ compromise that will increase risk of toxicity or mortality - Active serious infection not controlled by oral or intravenous antibiotics - Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year - Known hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV) - Active grade III-V cardiac failure as defined by the New York Heart Association Criteria - Patients with a cardiac ejection fraction (as measured by either multigated acquisition [MUGA] or echocardiogram) < 40%

Study Design


Related Conditions & MeSH terms


Intervention

Other:
bone marrow and/or peripheral blood samples withdrawal
bone marrow and/or peripheral blood samples evaluation

Locations

Country Name City State
Italy Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica Ancona
Italy Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia Bergamo
Italy Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia Bologna
Italy Asst Degli Spedali Civili Di Brescia - Uo Ematologia Brescia
Italy Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia Lecce
Italy Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia Mestre
Italy Ematologia ed Immunologia Clinica Perugia
Italy Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica Roma
Italy Aou Senese - Uoc Ematologia E Trapianti Siena
Italy Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia Vicenza

Sponsors (1)

Lead Sponsor Collaborator
Gruppo Italiano Malattie EMatologiche dell'Adulto

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Drug sensitivity profile Frequencies of alternative therapies identified for T-ALL patients baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02484430 - Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT04620655 - RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL N/A
Terminated NCT03519984 - EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Phase 1
Recruiting NCT04128501 - Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Phase 2
Recruiting NCT00501826 - Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 2
Withdrawn NCT02538926 - Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 2
Active, not recruiting NCT00408005 - Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Phase 3
Terminated NCT02767934 - Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Phase 2
Withdrawn NCT06210750 - Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Phase 2
Recruiting NCT03007147 - Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Phase 3
Recruiting NCT05602194 - Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Phase 3
Recruiting NCT03504644 - Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2